oxybutynin has been researched along with Mental Disorders in 6 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Mental Disorders: Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fixed-dose nicotine replacement therapy (NRT) is efficacious for smoking cessation in the general population of smokers." | 3.79 | Escalating doses of transdermal nicotine in heavy smokers: effects on smoking behavior and craving. ( Andriash, K; Busto, UE; Persad, D; Selby, P; Zack, M; Zawertailo, L, 2013) |
| " Patients with psychiatric illnesses have many unmet needs that may be filled through the benefits gained from transdermal treatments, such as reduced dosing frequency, effective control of plasma medication concentrations, improved tolerability, ability to check compliance visually, and avoidance of first-pass hepatic metabolism." | 2.61 | Patches: Established and Emerging Transdermal Treatments in Psychiatry. ( Citrome, L; Correll, CU; Zeni, CM, 2019) |
| "The results of the Parkinson's Disease Sleep Scale 2nd version (PDSS-2) were heterogeneous, and those on the Snaith-Hamilton Pleasure Scale (SHAPS) were not statistically significant (P = ." | 2.58 | Rotigotine transdermal patch for the treatment of neuropsychiatric symptoms in Parkinson's disease: A meta-analysis of randomized placebo-controlled trials. ( He, Y; Wang, HT; Wang, L; Yu, G, 2018) |
| " In all cases patients had been treated according to a normal dosage regimen." | 1.30 | [Neuropsychiatric adverse effects attributed to use of oxybutynin]. ( Kwee-Zuiderwijk, WJ; Stricker, BH; t'Veld, BA; van Puijenbroek, EP, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| t'Veld, BA | 1 |
| Kwee-Zuiderwijk, WJ | 1 |
| van Puijenbroek, EP | 1 |
| Stricker, BH | 1 |
| Movig, KL | 1 |
| Egberts, AC | 1 |
| Lenderink, AW | 1 |
| Leufkens, HG | 1 |
| Wang, HT | 1 |
| Wang, L | 1 |
| He, Y | 1 |
| Yu, G | 1 |
| Citrome, L | 1 |
| Zeni, CM | 1 |
| Correll, CU | 1 |
| Selby, P | 1 |
| Andriash, K | 1 |
| Zawertailo, L | 1 |
| Persad, D | 1 |
| Zack, M | 1 |
| Busto, UE | 1 |
| Prochaska, JJ | 1 |
| Fromont, SC | 1 |
| Ramo, DE | 1 |
| Young-Wolff, KC | 1 |
| Delucchi, K | 1 |
| Brown, RA | 1 |
| Hall, SM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Smoking While on Transdermal Nicotine Replacement Therapy: Effects on Craving and Cessation[NCT00289653] | 23 participants (Actual) | Interventional | 2005-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Expired Co levels were measured to confirm smoking status (NCT00289653)
Timeframe: measured at week 10
| Intervention | parts per million (Mean) |
|---|---|
| Enrolled Participants | 9.2 |
self reported # cigarettes per day (NCT00289653)
Timeframe: Week 10
| Intervention | cigarettes per day (Mean) |
|---|---|
| Enrolled Participants | 3.7 |
2 reviews available for oxybutynin and Mental Disorders
| Article | Year |
|---|---|
Rotigotine transdermal patch for the treatment of neuropsychiatric symptoms in Parkinson's disease: A meta-analysis of randomized placebo-controlled trials.
Topics: Dopamine Agonists; Humans; Mental Disorders; Parkinson Disease; Psychotropic Drugs; Randomized Contr | 2018 |
Patches: Established and Emerging Transdermal Treatments in Psychiatry.
Topics: Administration, Cutaneous; Humans; Mental Disorders; Psychotropic Drugs; Transdermal Patch | 2019 |
1 trial available for oxybutynin and Mental Disorders
| Article | Year |
|---|---|
Gender differences in a randomized controlled trial treating tobacco use among adolescents and young adults with mental health concerns.
Topics: Adolescent; Adolescent Health Services; Female; Gender Identity; Humans; Male; Mental Disorders; Men | 2015 |
3 other studies available for oxybutynin and Mental Disorders
| Article | Year |
|---|---|
[Neuropsychiatric adverse effects attributed to use of oxybutynin].
Topics: Aged; Aged, 80 and over; Child; Enuresis; Female; Humans; Male; Mandelic Acids; Mental Disorders; Pa | 1998 |
Association between oxybutynin and neuropsychiatric adverse effects not confirmed in daily practice.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cholinergic Antagonists; Drug Prescriptions; Drug Uti | 2001 |
Escalating doses of transdermal nicotine in heavy smokers: effects on smoking behavior and craving.
Topics: Administration, Cutaneous; Adult; Affect; Behavior, Addictive; Biomarkers; Carbon Monoxide; Comorbid | 2013 |